Havah Therapeutics Showcases Innovative Data for Breast Cancer
Havah Therapeutics is making waves in the field of biopharmaceuticals with its innovative approach to breast cancer treatment. The company, known for developing pioneering hormonal implant therapies, is set to present groundbreaking real-world patient data at the RiseUp for Breast Cancer Conference. This event promises to shed light on the therapeutic potential of their novel combination implant therapy. This therapy utilizes testosterone in conjunction with an aromatase inhibitor, anastrozole, targeting the androgen receptor and intervening in certain pathways that are linked to high breast cancer risks.
Details of the Important Presentation
During the conference, Havah Therapeutics will convey essential insights underlining their research and development efforts. The details for the presentation are as follows:
RiseUp for Breast Cancer Conference
November 1 – 3
Venue: San Francisco, CA
Presentation Title: Real World Study of the Effect of T+Ai on Background Parenchymal Enhancement (BPE)
Presenter: Wayne Tilley, PhD, Havah Therapeutics
Date/Time: Friday, November 1, 2:15 PM Pacific Time
About Havah Therapeutics
The vision of Havah Therapeutics extends beyond convention, focusing on advanced treatment solutions for hormonally sensitive cancers and various breast conditions. The company is on a mission to utilize natural hormonal mechanisms to ensure a safe treatment experience for women, minimizing side effects significantly. Their flagship product, T+Ai, consists of testosterone and anastrozole, a low-dose aromatase inhibitor, together providing three months of continuous therapeutic effects. This approach is designed to improve patient compliance while enhancing safety and efficacy.
Participation in Groundbreaking Studies
Havah Therapeutics is actively engaged in a pivotal Phase 2 platform study titled Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ, or RECAST DCIS. This study aims to tackle the progression risk of DCIS into invasive breast cancer, illuminating a path toward more proactive management of breast health.
Frequently Asked Questions
What is the main focus of Havah Therapeutics?
Havah Therapeutics specializes in developing hormonal implant therapies for treating breast cancers.
What will the presentation at the RiseUp for Breast Cancer Conference highlight?
The presentation will showcase real-world patient data and the therapeutic effects of their combination implant therapy.
Who is presenting at the conference?
Wayne Tilley, PhD of Havah Therapeutics will be the presenter.
What does the T+Ai product entail?
T+Ai is a combination of testosterone and anastrozole designed for continuous and effective therapeutic intervention.
What study is Havah currently involved in?
They are participating in the RECAST DCIS Phase 2 platform study to prevent progression to breast cancer.